<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="980978a7-5c16-4350-add2-dd7c88ecb91b"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">Cefadroxil Tablets, USP<br/>
      </content>
      <content styleCode="bold">Rx only</content>
   </title>
   <effectiveTime value="20241230"/>
   <setId root="4674a05c-fdef-4737-a4b8-e3229bdada9d"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="001627975" root="1.3.6.1.4.1.519.1"/>
            <name>Teva Pharmaceuticals USA, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="9f144fc7-104a-4e74-89c9-4adc9cf6bb4f"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250106"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0093-4059" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cefadroxil</name>
                        <formCode code="C42998" displayName="TABLET" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cefadroxil</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="1000"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="280111G160" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CEFADROXIL</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q525PA8JJB" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CEFADROXIL ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CELLULOSE, MICROCRYSTALLINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="50"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0093-4059-53" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20070131"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA062774" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20070131"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">9;3;4059</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_707b4733-15d6-4568-b667-678456844033">
               <id root="cdbe8cfd-d888-4496-a25e-4d5f5db5960d"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil tablets and other antibacterial drugs, cefadroxil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.</paragraph>
               </text>
               <effectiveTime value="20241230"/>
            </section>
         </component>
         <component>
            <section ID="LINK_f974e561-a320-452a-b807-11885d1d823f">
               <id root="86cd2229-2de0-4450-8ea8-d90f28bb933c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Cefadroxil, USP is a semisynthetic cephalosporin antibiotic intended for oral administration. It is a white to off-white crystalline powder. It is soluble in water and it is acid-stable. It is chemically designated as (6 <content styleCode="italics">R</content>,7<content styleCode="italics">R</content>)-7-[(<content styleCode="italics">R</content>)-2-amino-2-(<content styleCode="italics">p</content>-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate. It has the following structural formula:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>C<sub>16</sub>H<sub>17</sub>N<sub>3</sub>O<sub>5</sub>S•H<sub>2</sub>O          M.W. 381.40</paragraph>
                  <paragraph>Cefadroxil tablets, USP are available in a 1,000 mg strength and contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and microcrystalline cellulose.</paragraph>
               </text>
               <effectiveTime value="20241230"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Cefadroxil chemical structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="cefadroxil-tablet-062774-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e92d6df8-922f-4559-ac4c-8d23825cdc4d">
               <id root="66023561-1d46-42d1-b9ff-797119875fd1"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Cefadroxil is rapidly absorbed after oral administration. Following single doses of 500 mg and 1000 mg, average peak serum concentrations were approximately 16 and 28 mcg/mL, respectively. Measurable levels were present 12 hours after administration. Over 90% of the drug is excreted unchanged in the urine within 24 hours. Peak urine concentrations are approximately 1800 mcg/mL during the period following a single 500 mg oral dose. Increases in dosage generally produce a proportionate increase in cefadroxil urinary concentration. The urine antibiotic concentration, following a 1 g dose, was maintained well above the MIC of susceptible urinary pathogens for 20 to 22 hours.</paragraph>
               </text>
               <effectiveTime value="20241230"/>
               <component>
                  <section ID="LINK_7dc3e3e8-5602-44df-9120-7208d1906354">
                     <id root="bb36f44e-1114-40e0-8d67-22833944702c"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>Microbiology</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">In vitro </content>tests demonstrate that the cephalosporins are bactericidal because of their inhibition of cell-wall synthesis. Cefadroxil has been shown to be active against the following organisms both <content styleCode="italics">in vitro </content>and in clinical infections (see <content styleCode="bold">INDICATIONS AND USAGE</content>):</paragraph>
                        <paragraph>
                           <content styleCode="italics">Beta-hemolytic streptococci</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Staphylococci</content>, including penicillinase-producing strains</paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus (Diplococcus) pneumoniae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Escherichia coli</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Proteus mirabilis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Klebsiella </content>species</paragraph>
                        <paragraph>
                           <content styleCode="italics">Moraxella (Branhamella) catarrhalis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Note: </content>Most strains of <content styleCode="italics">Enterococcus faecalis </content>(formerly <content styleCode="italics">Streptococcus faecalis</content>) and <content styleCode="italics">Enterococcus faecium </content>(formerly <content styleCode="italics">Streptococcus faecium</content>) are resistant to cefadroxil. It is not active against most strains of <content styleCode="italics">Enterobacter </content>species, <content styleCode="italics">Morganella morganii </content>(formerly <content styleCode="italics">Proteus morganii</content>), and <content styleCode="italics">P. vulgaris. </content>It has no activity against <content styleCode="italics">Pseudomonas </content>species and <content styleCode="italics">Acinetobacter calcoaceticus </content>(formerly <content styleCode="italics">Mima </content>and <content styleCode="italics">Herellea </content>species).</paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                     <component>
                        <section ID="LINK_4fba2068-78ae-4b4d-b535-545f0a0fe3bb">
                           <id root="07ea9855-9903-4321-be85-92e32bde9d10"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Susceptibility Testing</title>
                           <text>
                              <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC. </paragraph>
                           </text>
                           <effectiveTime value="20241230"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_9266f779-631f-44ba-b5c1-0c005880964a">
               <id root="c2ce23bd-e58c-4966-8467-f20f88cf74ee"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Cefadroxil tablets are indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases:</paragraph>
                  <paragraph>Urinary tract infections caused by <content styleCode="italics">E. coli</content>, <content styleCode="italics">P. mirabilis</content>, and <content styleCode="italics">Klebsiella </content>species.</paragraph>
                  <paragraph>Skin and skin structure infections caused by staphylococci and/or streptococci.</paragraph>
                  <paragraph>Pharyngitis and/or tonsillitis caused by <content styleCode="italics">Streptococcus pyogenes </content>(Group A beta-hemolytic streptococci).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Note: </content>Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil for the prophylaxis of subsequent rheumatic fever are not available.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Note: </content>Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated.</paragraph>
                  <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil tablets and other antibacterial drugs, cefadroxil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
               </text>
               <effectiveTime value="20241230"/>
            </section>
         </component>
         <component>
            <section ID="LINK_e50814ff-c90e-4bb6-892d-00c3093012b1">
               <id root="eb1039f2-bdaf-4212-b092-19f305820706"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Cefadroxil tablets are contraindicated in patients with known allergy to the cephalosporin group of antibiotics.</paragraph>
               </text>
               <effectiveTime value="20241230"/>
            </section>
         </component>
         <component>
            <section ID="LINK_e0bbea1a-4ea5-4f95-99b3-4750372f2cdc">
               <id root="37493bed-9da1-4439-9cbf-56685fd22e71"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>BEFORE THERAPY WITH CEFADROXIL IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFADROXIL, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-SENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY.</paragraph>
                  <paragraph>IF AN ALLERGIC REACTION TO CEFADROXIL OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Clostridium difficile</content> associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefadroxil, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                  <paragraph>
                     <content styleCode="italics">C. difficile</content> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile</content> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. </paragraph>
                  <paragraph>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <content styleCode="italics">C. difficile</content> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated. </paragraph>
               </text>
               <effectiveTime value="20241230"/>
            </section>
         </component>
         <component>
            <section ID="LINK_96d1a6c2-948e-4150-afdb-0c732f0d982c">
               <id root="a26a172b-2b5c-4198-826a-0a26899c2b35"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20241230"/>
               <component>
                  <section ID="LINK_67a496b6-476f-490f-8671-bd9824f5c28e">
                     <id root="7d05f31c-a2f9-4fce-89a3-ba98bfc63dfc"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Cefadroxil should be used with caution in the presence of markedly impaired renal function (creatinine clearance rate of less than 50 mL/min/1.73 m<sup>2</sup>). (See <content styleCode="bold">DOSAGE AND ADMINISTRATION</content>.) In patients with known or suspected renal impairment, careful clinical observation and appropriate laboratory studies should be made prior to and during therapy.</paragraph>
                        <paragraph>Prescribing cefadroxil tablets in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                        <paragraph>Prolonged use of cefadroxil may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.</paragraph>
                        <paragraph>Cefadroxil should be prescribed with caution in individuals with history of gastrointestinal disease particularly colitis.</paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4d0c6d6b-9d96-4e8e-85ee-53c02a38f689">
                     <id root="f9b685e0-2988-4705-8071-afe78d5bc28e"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for Patients</title>
                     <text>
                        <paragraph>Patients should be counseled that antibacterial drugs including cefadroxil tablets should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cefadroxil tablets are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cefadroxil tablets or other antibacterial drugs in the future.</paragraph>
                        <paragraph>Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible. </paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4f1a6f03-17ba-4582-9d88-b618989b50e1">
                     <id root="9599f8ea-1771-4da0-9bc9-0b1a4cf0aa87"/>
                     <code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Positive direct Coombs’ tests have been reported during treatment with the cephalosporin antibiotics. In hematologic studies or in transfusion cross-matching procedures when antiglobulin tests are performed on the minor side or in Coombs’ testing of newborns whose mothers have received cephalosporin antibiotics before parturition, it should be recognized that a positive Coombs’ test may be due to the drug.</paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_58899952-8c88-4a6e-846f-b053955f0d8b">
                     <id root="cbced7a9-65e6-4f41-9eec-eb1bc92a18dd"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No long-term studies have been performed to determine carcinogenic potential. No genetic toxicity tests have been performed.</paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0bf1dcb3-7447-4815-8cf8-6098656df553">
                     <id root="64653771-5890-45b3-a310-7139ec0aa049"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20241230"/>
                     <component>
                        <section ID="LINK_853f7871-a009-4aab-9207-915d82649c0a">
                           <id root="f91cba04-fd6a-4c9c-af83-ef9b7b85b0af"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>Teratogenic Effects</title>
                           <effectiveTime value="20241230"/>
                           <component>
                              <section ID="LINK_98bd863a-5ceb-4be8-8c1e-ba21e2b50c55">
                                 <id root="bbfedaab-4f3b-4b57-9c0b-5ce9af381ef0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>Pregnancy category B</title>
                                 <text>
                                    <paragraph>Reproduction studies have been performed in mice and rats at doses up to 11 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to cefadroxil monohydrate. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</paragraph>
                                 </text>
                                 <effectiveTime value="20241230"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5016940d-b1b0-4f0b-8c86-9095e78e3b43">
                     <id root="a31f46a4-ead2-4dba-a97c-1483ab042e12"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>Labor and Delivery</title>
                     <text>
                        <paragraph>Cefadroxil has not been studied for use during labor and delivery. Treatment should only be given if clearly needed.</paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_34c45cff-3ca3-4789-8cf4-b7bb150dae2a">
                     <id root="91267bef-42ec-4a0d-a10e-28b150552c7c"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>Caution should be exercised when cefadroxil monohydrate is administered to a nursing mother.</paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_41249157-4bbe-4482-8bdd-2745d7c012bf">
                     <id root="a4793183-44f3-4e50-842c-f0045e2e27d3"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>(See <content styleCode="bold">DOSAGE AND ADMINISTRATION</content>.)</paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e19e03ea-68c5-4e6e-a7bc-67a0e3ccdc2f">
                     <id root="d37a6b3b-cce3-424a-a424-3c7d2d39d1c8"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>Of approximately 650 patients who received cefadroxil for the treatment of urinary tract infections in three clinical trials, 28% were 60 years and older, while 16% were 70 years and older. Of approximately 1,000 patients who received cefadroxil for the treatment of skin and skin structure infection in 14 clinical trials, 12% were 60 years and older while 4% were 70 years and over. No overall differences in safety were observed between the elderly patients in these studies and younger patients. Clinical studies of cefadroxil for the treatment of pharyngitis or tonsillitis did not include sufficient numbers of patients 65 years and older to determine whether they respond differently from younger patients. Other reported clinical experience with cefadroxil has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</paragraph>
                        <paragraph>Cefadroxil is substantially excreted by the kidney, and dosage adjustment is indicated for patients with renal impairment (see <content styleCode="bold">DOSAGE AND ADMINISTRATION</content>,<content styleCode="bold"> Renal Impairment</content>). Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_babd5c93-bbb3-42cb-8bb3-24a96867daca">
               <id root="06d596c7-5b98-4f13-8ee9-1f9b55de2919"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <effectiveTime value="20241230"/>
               <component>
                  <section ID="LINK_fc9d67fb-2e09-41b4-be19-0314524b47b9">
                     <id root="1b90b85d-d476-474a-85b8-ba552fa7025a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Gastrointestinal</title>
                     <text>
                        <paragraph>Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see <content styleCode="bold">WARNINGS</content>). Dyspepsia, nausea and vomiting have been reported rarely. Diarrhea has also occurred.</paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ddf14db1-954b-4472-bac1-5e2534b5cddb">
                     <id root="b866da6b-0acd-4b02-ab83-87d58dd4c484"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Hypersensitivity</title>
                     <text>
                        <paragraph>Allergies (in the form of rash, urticaria, angioedema, and pruritus) have been observed. These reactions usually subsided upon discontinuation of the drug. Anaphylaxis has also been reported.</paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_870440c0-8209-4507-9639-a30fd498b9cd">
                     <id root="a703edad-42b7-4880-9614-97313c848fba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Other</title>
                     <text>
                        <paragraph>Other reactions have included hepatic dysfunction including cholestasis and elevations in serum transaminase, genital pruritus, genital moniliasis, vaginitis, moderate transient neutropenia, fever. Agranulocytosis, thrombocytopenia, idiosyncratic hepatic failure, erythema multiforme, Stevens-Johnson syndrome, serum sickness, and arthralgia have been rarely reported.</paragraph>
                        <paragraph>In addition to the adverse reactions listed above which have been observed in patients treated with cefadroxil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics:</paragraph>
                        <paragraph>Toxic epidermal necrolysis, abdominal pain, superinfection, renal dysfunction, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, prolonged prothrombin time, positive Coombs’ test, increased BUN, increased creatinine, elevated alkaline phosphatase, elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), elevated bilirubin, elevated LDH, eosinophilia, pancytopenia, neutropenia.</paragraph>
                        <paragraph>Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment, when the dosage was not reduced (see <content styleCode="bold">DOSAGE AND ADMINISTRATION </content>and <content styleCode="bold">OVERDOSAGE</content>). If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_3c268ce0-d8c6-4c99-8c55-584d0b4ff531">
               <id root="3674a8ee-9b62-4390-87a8-b434588f652c"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>A study of children under six years of age suggested that ingestion of less than 250 mg/kg of cephalosporins is not associated with significant outcomes. No action is required other than general support and observation. For amounts greater than 250 mg/kg, induce gastric emptying.</paragraph>
                  <paragraph>In five anuric patients, it was demonstrated that an average of 63% of a 1 g oral dose is extracted from the body during a 6 to 8 hour hemodialysis session.</paragraph>
               </text>
               <effectiveTime value="20241230"/>
            </section>
         </component>
         <component>
            <section ID="LINK_4e5ddbca-d7d1-49dd-86ef-14e032bcf3b3">
               <id root="a16cde3d-3f7f-410d-90f9-7f3b6066672e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Cefadroxil tablets are acid-stable and may be administered orally without regard to meals. Administration with food may be helpful in diminishing potential gastrointestinal complaints occasionally associated with oral cephalosporin therapy.</paragraph>
               </text>
               <effectiveTime value="20241230"/>
               <component>
                  <section ID="LINK_f3a9baa9-3995-4d03-b511-d3567e3d57f0">
                     <id root="d6338179-beb7-4b5f-9a91-d197c8c22683"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Adults</title>
                     <effectiveTime value="20241230"/>
                     <component>
                        <section ID="LINK_ba2bf7f8-c926-4087-83f0-cf6cb092e5b4">
                           <id root="97a91fb3-3d75-4bf5-833a-9bd57d7ccbd9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Urinary Tract Infections</title>
                           <text>
                              <paragraph>For uncomplicated lower urinary tract infections (i.e., cystitis) the usual dosage is 1 or 2 g per day in a single (q.d.) or divided doses (b.i.d.).</paragraph>
                              <paragraph>For all other urinary tract infections the usual dosage is 2 g per day in divided doses (b.i.d.).</paragraph>
                           </text>
                           <effectiveTime value="20241230"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_accb08c0-4c77-426a-8c1c-9d8d89ce4fd8">
                           <id root="4dc750ec-d6e8-474c-bab5-9387382971c7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Skin and Skin Structure Infections</title>
                           <text>
                              <paragraph>For skin and skin structure infections the usual dosage is 1 g per day in single (q.d.) or divided doses (b.i.d.).</paragraph>
                           </text>
                           <effectiveTime value="20241230"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_a9691b6f-f83f-4a00-b6e0-d4897835b10d">
                           <id root="25897a22-e0ac-4d32-87dc-ed86315c387f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Pharyngitis and Tonsillitis</title>
                           <text>
                              <paragraph>Treatment of group A beta-hemolytic streptococcal pharyngitis and tonsillitis - 1 g per day in single (q.d.) or divided doses (b.i.d.) for 10 days.</paragraph>
                           </text>
                           <effectiveTime value="20241230"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2bbe1d50-1ba2-4cb7-98a4-e91439ae9ebb">
                     <id root="00a7d08b-5a5e-42d7-9b18-75bd7605f563"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Children</title>
                     <text>
                        <paragraph>For urinary tract infections, the recommended daily dosage for children is 30 mg/kg/day in divided doses every 12 hours. For pharyngitis, tonsillitis, and impetigo, the recommended daily dosage for children is 30 mg/kg/day in a single dose or in equally divided doses every 12 hours. For other skin and skin structure infections, the recommended daily dosage is 30 mg/kg/day in equally divided doses every 12 hours. In the treatment of beta-hemolytic streptococcal infections, a therapeutic dosage of cefadroxil tablets should be administered for at least 10 days.</paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6c38ea84-8b9f-4cff-9f42-b29e42128846">
                     <id root="3e2cdb5e-911c-49a3-a8c9-ebe65c3a1839"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Renal Impairment</title>
                     <text>
                        <paragraph>In patients with renal impairment, the dosage of cefadroxil monohydrate should be adjusted according to creatinine clearance rates to prevent drug accumulation. The following schedule is suggested. In adults, the initial dose is 1000 mg of cefadroxil tablets and the maintenance dose (based on the creatinine clearance rate [mL/min/1.73 m<sup>2</sup>]) is 500 mg at the time intervals listed below.</paragraph>
                        <table>
                           <col width="24%"/>
                           <col width="18%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule">
                                    <paragraph>
                                       <content styleCode="bold">Creatinine Clearances</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Dosage Interval</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Lrule">
                                    <paragraph>0 to 10 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>36 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Lrule">
                                    <paragraph>10 to 25 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>24 hours</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Lrule">
                                    <paragraph>25 to 50 mL/min</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Lrule Rrule">
                                    <paragraph>12 hours</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Patients with creatinine clearance rates over 50 mL/min may be treated as if they were patients having normal renal function.</paragraph>
                     </text>
                     <effectiveTime value="20241230"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_9ea60c24-683c-444f-93f0-6082ef5e930c">
               <id root="0e047978-75e8-4757-bb41-21de16dea15f"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Cefadroxil tablets USP, 1,000 mg are available as white to off-white, oval-shaped, scored tablets, debossed “93” on one side (with a bisect cut between the 9 and 3) and “4059” on the other side, containing cefadroxil monohydrate equivalent to 1,000 mg of cefadroxil, packaged in bottles of 50 tablets (NDC 0093-4059-53).</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>Dispense in a tight container as defined in the USP. Use child-resistant closure (as required).</paragraph>
                  <paragraph>Keep this and all medications out of the reach of children.</paragraph>
               </text>
               <effectiveTime value="20241230"/>
            </section>
         </component>
         <component>
            <section ID="LINK_9712e0c1-ddc6-4430-b643-d8cf03cde8a4">
               <id root="a5e3d4c9-e909-4456-a0b6-b42ac219c894"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>Manufactured For:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Teva Pharmaceuticals</content>
                     <br/>
Parsippany, NJ 07054</paragraph>
                  <paragraph>Rev. F 12/2024</paragraph>
               </text>
               <effectiveTime value="20241230"/>
            </section>
         </component>
         <component>
            <section ID="LINK_5da4d214-f3bf-4081-a1ae-886114bea5c2">
               <id root="64b519c4-dddf-4b33-a07e-d71f4edd7724"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 0093-4059-53</paragraph>
                  <paragraph>Cefadroxil Tablets, USP</paragraph>
                  <paragraph>1000 mg</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>50 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20241230"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Cefadroxil Tablets USP 1000 mg 50s Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="cefadroxil-tablet-062774-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>